A commentary examines the unique challenges and merits of developing cannabis-based medicines from whole-plant preparations versus synthesized individual cannabinoids, noting how legalization complicates both pathways.
Read this if you want to understand why some cannabis medicines are whole-plant products while others are synthetic, and what the trade-offs are.
Two competing pathways: botanical vs single-molecule cannabinoid drug development
What the researchers found
Researchers outlined the two parallel approaches to cannabinoid drug development and their respective challenges. The botanical approach derives medications directly from the cannabis plant, offering the potential entourage effect but facing challenges with standardization, batch consistency, and regulatory complexity. The single-molecule approach synthesizes individual cannabinoids for pharmaceutical development, offering precise dosing and regulatory clarity but potentially missing synergistic effects.
Both approaches face unique complications from the expanding legalization of cannabis. Legalization creates a situation where patients can access unregulated cannabis products that compete with pharmaceutical development, potentially undermining the incentive to conduct expensive clinical trials.
The commentary also highlighted regulatory challenges, noting that the botanical approach must navigate agricultural regulation alongside pharmaceutical approval, while the single-molecule approach faces competition from the very plant compounds it seeks to purify. Public health considerations were discussed, including the need for quality control regardless of the regulatory pathway chosen.
Why it matters
The pathway through which cannabis medicines are developed has direct implications for patients. Whole-plant products may offer broader therapeutic effects through the entourage mechanism, but single-molecule drugs offer more precise dosing and better-studied safety profiles. Understanding this debate helps patients and clinicians make informed choices.
The numbers in context
Two development pathways: botanical (plant-derived) and single molecule (synthesized). Two synthetic cannabinoid drugs FDA-approved at time of publication. Multiple state-level legalization programs creating competing access pathways.
How the study worked
This was a commentary discussing the two major cannabinoid drug development strategies, their challenges, and the impact of legalization on pharmaceutical development.
What this study cannot tell us
This is a commentary reflecting expert opinions rather than presenting new data. The discussion is framed within the US regulatory context and may not fully apply to other jurisdictions. The commentary was published before several significant regulatory developments.
How to read the evidence
This is an expert commentary providing moderate-level analysis of the drug development landscape.
When this study was published
Published in 2018, before several major regulatory developments in cannabinoid medicine.
The bigger picture
This tension between botanical and pharmaceutical approaches is unique to cannabis medicine. No other plant-based medicine has the same combination of widespread public access, political legalization, and simultaneous pharmaceutical development. How this tension resolves will shape the future of cannabis medicine for decades.
Questions still open
- Can the pharmaceutical industry develop profitable cannabis medicines when patients can grow or purchase the plant? Will botanical standardization ever achieve the consistency required for pharmaceutical-grade products? How should regulatory frameworks balance access with safety?
Common questions
What is the difference between whole-plant and synthetic cannabis medicine?
Why does legalization affect cannabis drug development?
Read the original research
Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.
International review of psychiatry (Abingdon, England), 30(3), 277-284
Citation
Bonn-Miller, Marcel O; ElSohly, Mahmoud A; Loflin, Mallory J E; Chandra, Suman; Vandrey, Ryan. (2018). Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.. International review of psychiatry (Abingdon, England), 30(3), 277-284. https://doi.org/10.1080/09540261.2018.1474730
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk